Evaluation of flat dosing for nivolumab (NIVO) plus ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)

A. S. Tsao, P. Baas, A. Nowak, G. Zalcman, N. Fujimoto, S. Peters, C. Baudelet, P. Aanur, M. Osawa, A. Tendolkar, Y. Feng, J. Sheng

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S1445-S1445
Number of pages1
JournalAnnals of Oncology
Publication statusPublished - Dec 2020
EventESMO Immuno-Oncology Virtual Congress -
Duration: 9 Dec 202012 Dec 2020

Cite this